Pharmaron Beijing Co., Ltd. (FRA:17Q1)

Market Cap	9.50B +33.0%
Revenue (ttm)	1.97B +16.3%
Net Income	220.69M +24.0%
EPS	0.12 +21.6%
Shares Out	n/a
PE Ratio	43.04
Forward PE	31.21
Dividend	0.03 (0.77%)
Ex-Dividend Date	Jul 7, 2026

Volume	16
Open	3.240
Previous Close	3.200
Day's Range	3.240 - 3.320
52-Week Range	1.600 - 3.680
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Commercial Physical and Biological Research
• Founded: 2004
• Employees: 27,316
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 17Q1

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error